{"preliminary_commentary":{"by_channel":{"podcast":3,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05227664","nct_id":"NCT05227664","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05227664. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects receive AK117 and AK112 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.","label":"cohort1(AK117 +AK112 +Nab-Paclitaxel/ Paclitaxel)","type":"EXPERIMENTAL"},{"description":"Subjects receive AK117 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.","label":"cohort2(AK117 +Nab-Paclitaxel/ Paclitaxel)","type":"EXPERIMENTAL"},{"description":"Subjects receive AK112 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.","label":"cohort3(AK112 +Nab-Paclitaxel/ Paclitaxel)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-06-30","type":"ESTIMATED"},"conditions":["Metastatic Triple-negative Breast Cancer","Locally Advanced Triple-negative Breast Cancer"],"enrollment":{"count":120,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"AK117","otherNames":[],"type":"DRUG"},{"name":"AK112","otherNames":[],"type":"DRUG"},{"name":"Nab paclitaxel","otherNames":[],"type":"DRUG"},{"name":"paclitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-16","lead_sponsor":"Akeso","official_title":"A Phase II Study of AK117/AK112 in Combination With Chemotherapy for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective response rates (ORR)","timeFrame":"Up to approximately 2 years"},{"measure":"Number of participants with adverse events (AEs)","timeFrame":"Up to approximately 2 years"}],"references":[{"citation":"Shao X, Tian C, Chen Z, Huang J, Wang Y, Sun T, Yi T, Wu Y, Sun W, Yu X, Wang ZM, Li B, Xia Y, Wang X, Ouyang Q. First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial. Nat Med. 2026 Aug 12. doi: 10.1038/s41591-026-04564-7. Online ahead of print.","pmid":"42587052","type":"DERIVED"}],"start_date":{"date":"2022-03-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05227664"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05227664"}